No article text was recorded for this version.
immune checkpoint inhibition
Version 1 of 119 papers20 conceptsfrozen 2026-10-04
Papers in this version
- Blog: IDDF2020-ABS-0201 Targeting hepatoma-intrinsic pparγ signaling overcomes immune checkpoint therapy resistance by inflaming the tumor microenvironment
- Blog: Progress on Pathogenesis Rccs and Related Treatments
- Blog: Advances in PD-1/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives
- Blog: Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives
- Blog: Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases
- Blog: Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application
- Blog: Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302
- Blog: An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models
- Blog: New antibody approaches to lymphoma therapy
- Blog: Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?
- Blog: A Patient With Hepatocellular Carcinoma and Lung Metastasis Successfully Underwent Curative Surgery Following the Downstaging Treatment: A Case Report
- Blog: Effect of perioperative flurbiprofen axetil on long‐term survival of patients with esophageal carcinoma who underwent thoracoscopic esophagectomy: A retrospective study
- Blog: Progress in the study of metastatic mechanism of colorectal cancer in vivo
- Blog: Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy
- Blog: LILRB4 regulates circadian disruption-induced mammary tumorigenesis via non-canonical WNT signaling pathway
- Blog: Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy
- Blog: Bronchoscopic Interventional Therapy Combined With Pembrolizumab in the Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma: A Case Report
- Blog: The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma
- Blog: Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_immune_checkpoint_inhibition_72393430,
title = {immune checkpoint inhibition},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/immune-checkpoint-inhibition/rdr_7239343094c3415c900bf452216c55e8},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-21},
}This exact version (version 1, frozen text):
@misc{lacuna_immune_checkpoint_inhibition_72393430_v1,
title = {immune checkpoint inhibition},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/immune-checkpoint-inhibition/rdr_7239343094c3415c900bf452216c55e8/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-21},
}